Doxil-type PEGylated liposomal doxorubicin
HSPC/cholesterol/DSPE-PEG2000 PEGylated liposomes with an ammonium-sulfate-gradient doxorubicin-loading context.
Applicable scenario
Composition reference for PEGylated liposomal doxorubicin and remote-loading studies. Compare with non-PEGylated Myocet when evaluating how lipid composition changes a formulation.
Import to Workspace
Open or scan to import into Workspace, jump to Modules and open this Recipe in the editor.
Formulation tables
PEGylated lipid membrane
| Component | Molar percentage | Role |
|---|---|---|
| HSPC | 56.4 mol% | High-transition-temperature membrane lipid |
| Cholesterol | 38.3 mol% | Membrane composition |
| DSPE-PEG2000 | 5.3 mol% | PEGylated lipopolymer |
Research PLD context
| Parameter | Value | Source scope |
|---|---|---|
| Total lipid | 16 mg/mL | Wei et al. research PLDs |
| Total doxorubicin | 2 mg/mL | Wei et al. research PLDs |
| Ammonium sulfate | 250 mM | Research preparation and gradient condition |
| Diameter | 75–85 nm; PDI 0.05–0.07 | Research PLDs, not a release specification |
Source values and calculations
- The membrane molar composition is 56.4:38.3:5.3 HSPC:cholesterol:DSPE-PEG2000, totaling 100 mol%.
- The research PLDs contain 16 mg/mL total lipid and 2 mg/mL total doxorubicin; the Doxil-type membrane composition is shared across the compared formulations.
- A 250 mM ammonium sulfate preparation is one of the research conditions. Wei et al. report stable nanocrystallization at intraliposomal ammonium sulfate ≥200 mM, not a universal concentration for every remote-loading design.
Literature source
Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release 160, 117–134 (2012).
Source locator: Composition and preparation of Doxil
Read the original source · DOI: 10.1016/j.jconrel.2012.03.020
Related source: Wei X et al. Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance. ACS Omega 3, 2508–2517 (2018).
Source locator: Methods, PLD composition and preparation; Table 1 and Figure 2
Read the related source · DOI: 10.1021/acsomega.7b01235
Related source: Bulbake U et al. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9, 12 (2017).
Source locator: Table 1 and Section 3.1.1, Doxil
Read the related source · DOI: 10.3390/pharmaceutics9020012
Editorial source check: 2026-11-09. Verify the original publication, actual stock concentrations and local safety requirements before use. Research use only; not clinical instructions.